Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589024 | 0.96 | GPR6 (0.34) | GPR6HRH3TP53MAPTCHRM2 | |
| SCHEMBL3595718 | 0.96 | GPR6 (0.35) | GPR6HRH3TP53MAPTCHRM2 | |
| SCHEMBL3595378 | 0.94 | GPR6 (0.34) | GPR6HRH3 | |
| SCHEMBL3589355 | 0.92 | GPR6 (0.35) | GPR6HRH3TP53MAPTCHRM2 | |
| SCHEMBL3592879 | 0.91 | HRH3 (0.44) | HRH3CHRM2 | |
| SCHEMBL3594452 | 0.90 | GPR6 (0.34) | GPR6 | |
| SCHEMBL3594150 | 0.89 | HRH3 (0.41) | GPR6HRH3CHRM2CHRM1ACHE | |
| SCHEMBL3596047 | 0.88 | SIGMAR1 (0.40) | GPR6HRH3CHRM2CHRM1CHRM4 | |
| SCHEMBL3602364 | 0.88 | AKR1C3 (0.37) | TP53MAPTCHRM2CHRM1CCR5 | |
| SCHEMBL3602359 | 0.88 | AKR1C3 (0.37) | TP53MAPTCHRM2CHRM1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | GPR6 154/4885HRH3 832/4885TP53 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.